Mereo BioPharma Group plc — Director's Dealing 2026

Feb 2, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Mereo BioPharma Group plc (MREO)
CIK: 0001719714
Period of Report: 2026-02-01

Reporting Person: Scots-Knight Denise (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-01	Share Options (Right to buy)	$0.44	A	1035000	Acquired	2036-02-01	American Depositary Shares (1035000)	Direct
2026-02-01	Share Options (Right to buy)	$1.00	A	345000	Acquired	2036-02-01	American Depository Shares (345000)	Direct
2026-02-01	Share Options (Right to buy)	$0.44	A	480000	Acquired	2036-02-01	American Depository Shares (480000)	Direct

Footnotes

F1: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.

F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F3: Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date.